#USA #San Diego #Avidity Biosciences #Del-zota #DMD44

Avidity Biosciences Unveils Innovative Findings on Del-Zota at the 30th World Muscle Society Congress

Avidity Biosciences, Inc. (Nasdaq: RNA), a cutting-edge biopharmaceutical enterprise based in San Diego, California, is set to make a significant impact at the upcoming 30th Annual International Congress of the World Muscle Society (WMS), which will take place from October 7-11, 2025, in Vienna, Austria. By presenting late-breaking oral and poster presentations focused on their experimental drug delpacibart zotadirsen (del-zota), the company aims to further understand its effects on Duchenne muscular dystrophy (DMD).

Building on Positive Data from EXPLORE44® Trials

The data Avidity will present during the congress aims to reinforce promising findings previously announced in September 2025. These indicated that del-zota has shown the potential to reverse the progression of DMD44, a form of muscular dystrophy. This substantial improvement was observed in various functional assessments for individuals living with DMD mutations eligible for exon 44 skipping. Notably, these results were drawn from participants continuously treated with del-zota for a year through Phase 1/2 EXPLORE44® and Phase 2 EXPLORE44-OLE™ trials.

Del-zota, an investigational therapy not yet approved by the FDA, is part of Avidity’s innovative approach to RNA therapeutics, specifically designed as Antibody Oligonucleotide Conjugates (AOCs™). These AOCs aim to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, targeting diseases previously unreachable by existing RNA treatments.

Key Presentations at the Congress

Avidity will feature two compelling presentations during the congress:
1. Oral Presentation by Dr. Kevin M. Flanigan:
Scheduled for October 11, 2025, from 12:33 to 12:45 p.m. CET, this talk will outline trends in improving functional and patient-reported outcomes among DMD patients treated with del-zota.
2. Poster Presentation by Dr. Aravindhan Veerapandiyan:
Taking place on October 8, 2025, from 2:30 to 3:30 p.m. CET, this presentation will cover insights into how del-zota increased dystrophin and improved muscle integrity markers in individuals with DMD, irrespective of their ambulatory status.

Both presentations will be accessible on Avidity’s website following the congress, making this crucial information available to a broader audience.

Avidity’s Mission and Future Perspectives

Avidity Biosciences is committed to improving lives by harnessing the power of innovative RNA therapies. Their unique AOC platform represents a crucial shift in how RNA therapies can be developed, targeting various disorders more effectively. The company is leading clinical development programs aimed at addressing rare muscular diseases such as myotonic dystrophy type 1 (DM1), DMD, and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity is advancing two precision cardiology candidates aimed at rare genetic cardiomyopathies and expanding its development pipeline through strategic partnerships.

While the early results of del-zota are encouraging, Avidity reminds stakeholders and viewers that these findings are subject to further validation and regulatory scrutiny. With the upcoming congress presenting an opportunity to engage with the scientific community and investors, Avidity aims to reshape approaches towards the treatment of muscular dystrophies and related conditions.

As Avidity prepares for the World Muscle Society Congress, it continues to advocate for transparency and collaboration in the scientific pursuit of medical advancements. Stay tuned for updates and insights as new data emerges from this promising area of research.